JATT III Acquisition Completes $60 Million IPO
JATT III Acquisition raised $60 million through the sale of 6 million shares at $10 each. Unlike the typical SPAC structure, the offering does not include units containing warrants or rights.
The company plans to use its SPAC structure to identify and complete a business combination with a healthcare or healthcare-related business, with a particular emphasis on biotechnology and broader life sciences.
JATT III Acquisition will trade on the Nasdaq under the symbol JTTT. Guggenheim Securities acted as the sole bookrunner for the offering.
Biotech Entrepreneur Leads New SPAC
JATT III Acquisition is led by Someit Sidhu, who serves as CEO and chairman.
Sidhu has founded and led several healthcare companies. He most recently served as CEO of Khanda Therapeutics. Earlier in his career, he founded a biotechnology company that was subsequently sold to Roivant Sciences.
His experience across healthcare and biotechnology provides the new SPAC with a management team focused specifically on the sector it intends to target.
Previous JATT SPACs Provide Track Record
JATT III Acquisition represents the latest SPAC sponsored by Sidhu.
His previous vehicle, JATT II Acquisition, completed a $60 million IPO in April 2026. Two months later, JATT II announced a merger agreement with preclinical biotechnology company Talawar Therapeutics. The transaction included a $225 million PIPE investment from Bain Capital, RA Capital and other investors.
Sidhu’s earlier SPAC, JATT Acquisition, completed its combination with hair-loss biotechnology company Zura Bio in 2023.
The previous transactions provide JATT III Acquisition with a sponsor that has already pursued business combinations in the healthcare and biotechnology sectors.
Focus on Biotechnology and Life Sciences
The new SPAC intends to target businesses operating across healthcare and healthcare-related industries, while placing primary emphasis on biotechnology and the broader life sciences market.
This focus could provide the company with access to businesses developing innovative therapies, platforms and other healthcare technologies. However, the company has not identified a specific acquisition target in the information provided.
The absence of a named target means the eventual investment opportunity will depend on the business combination that JATT III Acquisition ultimately selects and the terms of that transaction.
Risks and Considerations
As with other blank check companies, JATT III Acquisition’s future prospects depend substantially on its ability to identify an appropriate acquisition target and complete a transaction on favorable terms.
The company’s healthcare and biotechnology focus can also expose it to the sector-specific risks associated with development-stage businesses, including clinical, regulatory and commercialization uncertainties. However, the supplied information does not provide details regarding the company’s eventual target or its specific investment criteria beyond its stated focus.
The SPAC’s structure is also notable because the IPO consists of shares without the warrants or rights commonly attached to SPAC units.
Closing Outlook
JATT III Acquisition’s $60 million Nasdaq IPO adds another healthcare-focused SPAC to the public markets, with its strategy centered on biotechnology and life sciences businesses. The offering is led by Someit Sidhu, whose previous SPACs have completed transactions involving Zura Bio and Talawar Therapeutics. Investors will now be watching for the identification of JATT III Acquisition’s target and whether the sponsor can replicate its previous focus on healthcare and biotechnology opportunities.
